Mark Sirgo Biography and Net Worth

Director of BioDelivery Sciences International

Dr. Mark Sirgo is Chief Executive Officer of Aruna Bio. Dr. Sirgo brings over 35 years of pharmaceutical experience to Aruna Bio from drug development through global product commercialization. Most recently, Dr. Sirgo served as President and CEO of BioDelivery Sciences International (BDSI:Nasdaq), a specialty pharmaceutical company focused in CNS/pain. While leading BDSI, Dr. Sirgo was successful in raising nearly $600 million in capital through partnerships and financings to support the development, FDA approval and commercial launch of three products utilizing the company’s proprietary drug delivery technology.

Dr. Sirgo began his career in clinical development and transitioned in time to marketing at Glaxo, GlaxoWellcome and GlaxoSmithKline including Vice President of International OTC Development and Vice President of New Product Marketing. This included Dr. Sirgo’s responsibility for managing the development and FDA approval of Zantac 75 while at Glaxo Wellcome. Dr. Sirgo also served as Senior Vice President of Business Development at Pharmaceutical Product Development (PPDI: Nasdaq).

Along with his role at Aruna Bio, Dr. Sirgo serves on the Board of Directors for a number of pharmaceutical and medical diagnostic companies including BioDelivery Sciences, BioMerica, Inc (BMRX:Nasdaq), 9 Meters Biopharma (Nasdaq: NMTR), Ltd and formerly Salix Pharmaceuticals (SLXP:Nasdaq). He earned a Bachelor of Science in Pharmacy from The Ohio State University and a Doctor of Pharmacy from the Philadelphia College of Pharmacy and Sciences.

What is Mark A. Sirgo's net worth?: The estimated net worth of Mark A. Sirgo is at least $8.13 million as of July 1st, 2022. Mr. Sirgo owns 1,454,045 shares of BioDelivery Sciences International stock worth more than $8,128,112 as of April 23rd. This net worth approximation does not reflect any other assets that Mr. Sirgo may own. Learn More about Mark A. Sirgo's net worth.
How do I contact Mark A. Sirgo?: The corporate mailing address for Mr. Sirgo and other BioDelivery Sciences International executives is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. BioDelivery Sciences International can also be reached via phone at (919) 582-9050 and via email at [email protected]. Learn More on Mark A. Sirgo's contact information.
Has Mark A. Sirgo been buying or selling shares of BioDelivery Sciences International?: Mark A. Sirgo has not been actively trading shares of BioDelivery Sciences International during the last ninety days. Most recently, on Thursday, December 2nd, Mark A. Sirgo bought 18,587 shares of BioDelivery Sciences International stock. The stock was acquired at an average cost of $2.69 per share, with a total value of $49,999.03. Learn More on Mark A. Sirgo's trading history.
Who are BioDelivery Sciences International's active insiders?: BioDelivery Sciences International's insider roster includes John Golubieski (CFO & Chief Accounting Officer ), Kevin Kotler (Director), Mark Sirgo (Director), and James Vollins (Insider). Learn More on BioDelivery Sciences International's active insiders.

Mark A. Sirgo Insider Trading History at BioDelivery Sciences International

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/2/2021	Buy	18,587	$2.69	$49,999.03
11/11/2021	Buy	16,000	$3.20	$51,200.00
8/14/2020	Sell	200,000	$4.74	$948,000.00	1,206,095
5/8/2020	Sell	100,000	$5.07	$507,000.00	1,264,595
4/27/2020	Sell	100,000	$4.58	$458,000.00	1,364,595
4/15/2020	Sell	50,000	$4.13	$206,500.00	1,464,595
1/6/2020	Sell	18,600	$5.84	$108,624.00	1,523,934
10/17/2019	Sell	31,860	$5.15	$164,079.00	1,703,124
10/15/2019	Sell	103,321	$4.98	$514,538.58	1,703,124
9/19/2019	Sell	24,506	$4.79	$117,383.74	1,874,637
9/17/2019	Sell	157,177	$4.79	$752,877.83	1,874,637
6/25/2019	Sell	90,706	$4.39	$398,199.34	2,031,714
6/12/2019	Sell	484,752	$4.22	$2,045,653.44	2,559,803
3/21/2019	Sell	9,050	$5.20	$47,060.00	2,509,005
1/2/2019	Sell	9,175	$3.57	$32,754.75	506,187
12/27/2018	Sell	10,000	$2.91	$29,100.00	2,489,542
4/10/2018	Sell	100,000	$2.06	$206,000.00	2,585,966
1/19/2018	Sell	709,502	$2.73	$1,936,940.46	1,759,262
1/17/2018	Sell	108,000	$2.57	$277,560.00	1,759,262
1/3/2018	Sell	162,509	$2.78	$451,775.02	1,759,262
9/21/2017	Sell	201,373	$2.84	$571,899.32	1,509,262
9/20/2017	Sell	65,405	$2.75	$179,863.75	1,509,262
9/19/2017	Sell	24,516	$2.75	$67,419.00	1,509,262
9/18/2017	Sell	6,000	$2.85	$17,100.00	1,509,262
9/15/2017	Sell	54,833	$2.90	$159,015.70	1,509,262
9/14/2017	Sell	50,000	$2.95	$147,500.00	1,509,262
3/31/2017	Sell	110,895	$1.90	$210,700.50	1,670,157
6/16/2015	Sell	4,187	$7.97	$33,370.39
12/15/2014	Buy	2,500	$12.23	$30,575.00
9/4/2014	Buy	2,000	$15.04	$30,080.00
6/21/2013	Buy	3,400	$4.30	$14,620.00
12/21/2012	Buy	4,975	$4.02	$19,999.50

Mark A. Sirgo Buying and Selling Activity at BioDelivery Sciences International

BioDelivery Sciences International Company Overview

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Today's Range

Now: $5.59

$5.59

$5.60

50 Day Range

MA: $5.58

$5.54

$5.60

2 Week Range

Now: $5.59

$2.50

$5.62

Volume

2,090,567 shs

Average Volume

3,340,554 shs

Market Capitalization

$577.05 million

P/E Ratio

6.74

Dividend Yield

N/A

Beta

0.56

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report